CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 413 enrolled
Drug / intervention
insulin degludec/liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01392573
NCT01392573Phase 3Completed
CompareCT.gov

A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Jul 12, 2011·Updated Jan 3, 2019

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide and insulin degludec for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 413 participants across 86 sites in 7 countries.

Detailed Summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesBulgaria, Denmark, Hungary, India, Slovenia, Switzerland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2011
Enrollment StartNov 28, 2011
Primary CompletionOct 1, 2012
Study CompletionOct 4, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.0 years ago

Interventions

insulin degludec/liraglutidedrug

IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.

insulin degludecdrug

IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.